LANCL2
LanC-like protein 2
Also known as: GPR69B, LANC2_HUMAN, TASP
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NS86
- Gene
- LANCL2
- Ensembl
- ENSG00000132434
- Chromosome
- 7
- Canonical length
- 450 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
Enables phosphatidylinositol-3-phosphate binding activity; phosphatidylinositol-4-phosphate binding activity; and phosphatidylinositol-5-phosphate binding activity. Involved in negative regulation of DNA-templated transcription and positive regulation of abscisic acid-activated signaling pathway. Located in several cellular components, including cortical actin cytoskeleton; cytosol; and nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
450 residues, UniProt reviewed canonical sequence.
>Q9NS86|LANCL2
1 MGETMSKRLK LHLGGEAEME ERAFVNPFPD YEAAAGALLA SGAAEETGCV RPPATTDEPG
61 LPFHQDGKII HNFIRRIQTK IKDLLQQMEE GLKTADPHDC SAYTGWTGIA LLYLQLYRVT
121 CDQTYLLRSL DYVKRTLRNL NGRRVTFLCG DAGPLAVGAV IYHKLRSDCE SQECVTKLLQ
181 LQRSVVCQES DLPDELLYGR AGYLYALLYL NTEIGPGTVC ESAIKEVVNA IIESGKTLSR
241 EERKTERCPL LYQWHRKQYV GAAHGMAGIY YMLMQPAAKV DQETLTEMVK PSIDYVRHKK
301 FRSGNYPSSL SNETDRLVHW CHGAPGVIHM LMQAYKVFKE EKYLKEAMEC SDVIWQRGLL
361 RKGYGICHGT AGNGYSFLSL YRLTQDKKYL YRACKFAEWC LDYGAHGCRI PDRPYSLFEG
421 MAGAIHFLSD VLGPETSRFP AFELDSSKRDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LANCL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 23 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 23 nTPM
- hippocampal formation: 21 nTPM
- amygdala: 19 nTPM
- basal ganglia: 18 nTPM
- spinal cord: 15 nTPM
- hypothalamus: 14 nTPM
Single-cell type
- oligodendrocytes: 114 nCPM
- oligodendrocyte progenitor cells: 89 nCPM
- corticotrophs: 86 nCPM
- late spermatids: 82 nCPM
- brain excitatory neurons: 78 nCPM
- late primary spermatocytes: 78 nCPM
Immune cell
- T-reg: 2.6 nTPM
- intermediate monocyte: 1.9 nTPM
- myeloid DC: 1.9 nTPM
- MAIT T-cell: 1.7 nTPM
- classical monocyte: 1.5 nTPM
- memory CD8 T-cell: 1.5 nTPM
Brain region
- hippocampal formation: 36 nTPM
- cerebral cortex: 32 nTPM
- basal ganglia: 30 nTPM
- amygdala: 27 nTPM
- white matter: 27 nTPM
- hypothalamus: 21 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.46
- gnomAD pLI
- 0.31
- gnomAD missense Z
- 0.77
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 11% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- carbohydrate metabolic process
- negative regulation of DNA-templated transcription
- peptide modification
- positive regulation of abscisic acid-activated signaling pathway
Molecular functions
- ATP binding
- GTP binding
- phosphatidylinositol-3-phosphate binding
- phosphatidylinositol-4-phosphate binding
- phosphatidylinositol-5-phosphate binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LANCL2 as an antibody target. Whether an autoantibody or antibody against LANCL2 could matter depends on whether native LANCL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LANCL2 is annotated at the cell surface, where native LANCL2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LANCL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...